Immunologic Dysregulation and Hypercoagulability as a Pathophysiologic Background in COVID-19 Infection and the Immunomodulating Role of Colchicine
Vrachatis DA, Papathanasiou KA, Giotaki SG, Raisakis K, Kossyvakis C, Kaoukis A, Kolokathis F, Deftereos G, Iliodromitis KE, Avramides D, Bogossian H, Siasos G, Giannopoulos G, Reimers B, Lansky A, Tardif JC, Deftereos S. Immunologic Dysregulation and Hypercoagulability as a Pathophysiologic Background in COVID-19 Infection and the Immunomodulating Role of Colchicine. Journal Of Clinical Medicine 2021, 10: 5128. PMID: 34768648, PMCID: PMC8584586, DOI: 10.3390/jcm10215128.Peer-Reviewed Original ResearchImmunologic dysregulationPathophysiologic backgroundImmunomodulating capacitySARS-CoV-2 infectionEffective therapeutic modalityCOVID-19 infectionDate systematic reviewSARS-CoV-2Thrombotic pathwaysClinical featuresDisease complicationsImmunomodulating roleTherapeutic modalitiesPathophysiologic importanceSystematic reviewHealth systemNovel diseaseHypercoagulabilityComplicationsCOVID-19InfectionDysregulationPivotal roleSignificant numberDisease